Hyperthermia in cancer research

Current status

K. S. Bisht, P. Uma Devi

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

There are critical maximum temperatures above which irreversible damage occurs in cells and tissues. Exposure to high temperature, referred to as hypothermia (HT), can result in cell death, tissue damage or even death of the organism. Clinical application of HT as a primary treatment or as an adjuvant to radio/ /chemo- therapy of cancer is based on its ability to cause localized tumor tissue damage. Experimental data provide HT with a strong biological rationale. Early clinical experience suggested that HT will become an important modality as an adjuvant to radiotherapy in the treatment of human malignancies, but its application is currently limited to mainly superficial tumors. Its full realization as a treatment modality for cancer therapy awaits further laboratory investigations as well as controlled clinical trials. A better understanding of the biological mechanisms of its action, interaction with chemotherapeutic drugs and radiation damage, role of tumor microenvironment such as oxygen status and pH of tumors, and kinetics of thermotolerance can lead to refinement in its clinical implementation. The present review attempts to analyse the published literature during the last one and half decades.

Original languageEnglish
Pages (from-to)1183-1189
Number of pages7
JournalIndian Journal of Experimental Biology
Volume34
Issue number12
Publication statusPublished - 01-12-1996
Externally publishedYes

Fingerprint

Fever
Hypothermia
Research
Neoplasms
Therapeutics
Adjuvant Radiotherapy
Temperature
Tumor Microenvironment
Controlled Clinical Trials
Radio
Cell Death
Radiation
Oxygen
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Molecular Biology
  • Cell Biology

Cite this

Bisht, K. S., & Uma Devi, P. (1996). Hyperthermia in cancer research: Current status. Indian Journal of Experimental Biology, 34(12), 1183-1189.
Bisht, K. S. ; Uma Devi, P. / Hyperthermia in cancer research : Current status. In: Indian Journal of Experimental Biology. 1996 ; Vol. 34, No. 12. pp. 1183-1189.
@article{a277a0e8516343d3a7e6af0ca860c673,
title = "Hyperthermia in cancer research: Current status",
abstract = "There are critical maximum temperatures above which irreversible damage occurs in cells and tissues. Exposure to high temperature, referred to as hypothermia (HT), can result in cell death, tissue damage or even death of the organism. Clinical application of HT as a primary treatment or as an adjuvant to radio/ /chemo- therapy of cancer is based on its ability to cause localized tumor tissue damage. Experimental data provide HT with a strong biological rationale. Early clinical experience suggested that HT will become an important modality as an adjuvant to radiotherapy in the treatment of human malignancies, but its application is currently limited to mainly superficial tumors. Its full realization as a treatment modality for cancer therapy awaits further laboratory investigations as well as controlled clinical trials. A better understanding of the biological mechanisms of its action, interaction with chemotherapeutic drugs and radiation damage, role of tumor microenvironment such as oxygen status and pH of tumors, and kinetics of thermotolerance can lead to refinement in its clinical implementation. The present review attempts to analyse the published literature during the last one and half decades.",
author = "Bisht, {K. S.} and {Uma Devi}, P.",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "34",
pages = "1183--1189",
journal = "Journal of scientific & industrial research. C. Biological sciences",
issn = "0019-5189",
publisher = "National Institute of Science Communication",
number = "12",

}

Bisht, KS & Uma Devi, P 1996, 'Hyperthermia in cancer research: Current status', Indian Journal of Experimental Biology, vol. 34, no. 12, pp. 1183-1189.

Hyperthermia in cancer research : Current status. / Bisht, K. S.; Uma Devi, P.

In: Indian Journal of Experimental Biology, Vol. 34, No. 12, 01.12.1996, p. 1183-1189.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Hyperthermia in cancer research

T2 - Current status

AU - Bisht, K. S.

AU - Uma Devi, P.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - There are critical maximum temperatures above which irreversible damage occurs in cells and tissues. Exposure to high temperature, referred to as hypothermia (HT), can result in cell death, tissue damage or even death of the organism. Clinical application of HT as a primary treatment or as an adjuvant to radio/ /chemo- therapy of cancer is based on its ability to cause localized tumor tissue damage. Experimental data provide HT with a strong biological rationale. Early clinical experience suggested that HT will become an important modality as an adjuvant to radiotherapy in the treatment of human malignancies, but its application is currently limited to mainly superficial tumors. Its full realization as a treatment modality for cancer therapy awaits further laboratory investigations as well as controlled clinical trials. A better understanding of the biological mechanisms of its action, interaction with chemotherapeutic drugs and radiation damage, role of tumor microenvironment such as oxygen status and pH of tumors, and kinetics of thermotolerance can lead to refinement in its clinical implementation. The present review attempts to analyse the published literature during the last one and half decades.

AB - There are critical maximum temperatures above which irreversible damage occurs in cells and tissues. Exposure to high temperature, referred to as hypothermia (HT), can result in cell death, tissue damage or even death of the organism. Clinical application of HT as a primary treatment or as an adjuvant to radio/ /chemo- therapy of cancer is based on its ability to cause localized tumor tissue damage. Experimental data provide HT with a strong biological rationale. Early clinical experience suggested that HT will become an important modality as an adjuvant to radiotherapy in the treatment of human malignancies, but its application is currently limited to mainly superficial tumors. Its full realization as a treatment modality for cancer therapy awaits further laboratory investigations as well as controlled clinical trials. A better understanding of the biological mechanisms of its action, interaction with chemotherapeutic drugs and radiation damage, role of tumor microenvironment such as oxygen status and pH of tumors, and kinetics of thermotolerance can lead to refinement in its clinical implementation. The present review attempts to analyse the published literature during the last one and half decades.

UR - http://www.scopus.com/inward/record.url?scp=0030321844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030321844&partnerID=8YFLogxK

M3 - Review article

VL - 34

SP - 1183

EP - 1189

JO - Journal of scientific & industrial research. C. Biological sciences

JF - Journal of scientific & industrial research. C. Biological sciences

SN - 0019-5189

IS - 12

ER -